|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF716 |
Gene summary for ZNF716 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF716 | Gene ID | 441234 |
| Gene name | zinc finger protein 716 | |
| Gene Alias | ZNF716 | |
| Cytomap | 7p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A6NP11 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 441234 | ZNF716 | HCC1 | Human | Liver | HCC | 4.24e-05 | 1.30e+00 | 0.5336 |
| 441234 | ZNF716 | HCC2 | Human | Liver | HCC | 2.99e-18 | 1.42e+00 | 0.5341 |
| 441234 | ZNF716 | HCC5 | Human | Liver | HCC | 1.46e-13 | 2.28e+00 | 0.4932 |
| 441234 | ZNF716 | S014 | Human | Liver | HCC | 4.18e-04 | 1.36e-01 | 0.2254 |
| 441234 | ZNF716 | S016 | Human | Liver | HCC | 2.55e-03 | 1.11e-01 | 0.2243 |
| 441234 | ZNF716 | S029 | Human | Liver | HCC | 2.42e-03 | 2.08e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF716 | SNV | Missense_Mutation | rs782720409 | c.492N>C | p.Lys164Asn | p.K164N | A6NP11 | protein_coding | tolerated(0.07) | possibly_damaging(0.793) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF716 | SNV | Missense_Mutation | novel | c.76T>G | p.Ser26Ala | p.S26A | A6NP11 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF716 | SNV | Missense_Mutation | novel | c.313G>A | p.Asp105Asn | p.D105N | A6NP11 | protein_coding | tolerated(0.12) | possibly_damaging(0.801) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF716 | SNV | Missense_Mutation | novel | c.379N>C | p.Lys127Gln | p.K127Q | A6NP11 | protein_coding | deleterious(0.01) | benign(0.133) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF716 | SNV | Missense_Mutation | novel | c.546N>T | p.Lys182Asn | p.K182N | A6NP11 | protein_coding | tolerated(0.17) | benign(0.081) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF716 | SNV | Missense_Mutation | rs782597694 | c.698N>T | p.Arg233Ile | p.R233I | A6NP11 | protein_coding | tolerated(0.34) | benign(0.02) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF716 | SNV | Missense_Mutation | rs782649551 | c.100N>A | p.Asp34Asn | p.D34N | A6NP11 | protein_coding | tolerated(0.07) | benign(0.125) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF716 | SNV | Missense_Mutation | c.920N>A | p.Arg307His | p.R307H | A6NP11 | protein_coding | tolerated(0.62) | benign(0.006) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| ZNF716 | SNV | Missense_Mutation | c.1383N>T | p.Glu461Asp | p.E461D | A6NP11 | protein_coding | tolerated(0.06) | benign(0.253) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| ZNF716 | SNV | Missense_Mutation | c.714N>T | p.Glu238Asp | p.E238D | A6NP11 | protein_coding | tolerated(0.07) | probably_damaging(0.97) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |